Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Non-Current Debt (2018 - 2022)

Historic Non-Current Debt for Iterum Therapeutics (ITRM) over the last 5 years, with Q3 2022 value amounting to $9.3 million.

  • Iterum Therapeutics' Non-Current Debt rose 5158.13% to $9.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was $9.3 million, marking a year-over-year increase of 5158.13%. This contributed to the annual value of $6.9 million for FY2021, which is 6914.79% down from last year.
  • As of Q3 2022, Iterum Therapeutics' Non-Current Debt stood at $9.3 million, which was up 5158.13% from $8.5 million recorded in Q2 2022.
  • Over the past 5 years, Iterum Therapeutics' Non-Current Debt peaked at $22.5 million during Q4 2020, and registered a low of $5.3 million during Q2 2021.
  • For the 5-year period, Iterum Therapeutics' Non-Current Debt averaged around $11.7 million, with its median value being $9.3 million (2019).
  • Its Non-Current Debt has fluctuated over the past 5 years, first skyrocketed by 19458.36% in 2020, then tumbled by 7449.24% in 2021.
  • Over the past 5 years, Iterum Therapeutics' Non-Current Debt (Quarter) stood at $13.1 million in 2018, then tumbled by 41.7% to $7.6 million in 2019, then skyrocketed by 194.58% to $22.5 million in 2020, then crashed by 69.15% to $6.9 million in 2021, then surged by 34.17% to $9.3 million in 2022.
  • Its last three reported values are $9.3 million in Q3 2022, $8.5 million for Q2 2022, and $7.7 million during Q1 2022.